Interaction between LINC-ROR and Stemness State in Gastric Cancer Cells with Helicobacter pylori Infection.
Journal
Iranian biomedical journal
ISSN: 2008-823X
Titre abrégé: Iran Biomed J
Pays: Iran
ID NLM: 9814853
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
aheadofprint
Résumé
Large intergenic non-coding RNA regulator of reprogramming (LINC-ROR), as a cancer-related Long non-coding RNA, has vital roles in stem cell survival, pluripotency, differentiation, and self-renewal in human embryonic stem cell. However, cancer-related molecular mech¬anisms, its functional roles, and clinical value of LINC-ROR in gastric cancer (GC) remain unclear. In this study, we aimed to investigate probable interplay between LINC-ROR with SALL4 stemness regulator and their role with the development of the disease. The mRNA expression profile of LINC-ROR and SALL4 was assessed in tumoral and adjacent non-cancerous tissues of GC patients, using quantitative real-time PCR. Significant LINC-ROR underexpression and SALL4 overexpression were observed in 55.81% and 75.58% (p < 0.0001) of samples, respectively. The expression of LINC-ROR and SALL4 were significantly correlated with each other (p = 0.044). There was an association between the underexpression of LINC-ROR and sex, stage of tumor progression, tumor type, and location of tumor (p < 0.05), and Helicobacter pylori infection with SALL4 expression (p = 0.036). There were also significant correlations between concomitant mRNA expression of SALL4 and LINC-ROR in tumors located at distal noncardiac, positive for H. pylori infection, tumors with invasion into the muscle layer of the stomach, and grade II tumor (p < 0.05). The clinical results of the SALL4-LINC-ROR association propose a probable functional interaction between these markers in tumor maintenance and aggressiveness. Our study can help to understand one of the mechanisms involved in the progression of gastric cancer through the function of these regulators.
Sections du résumé
BACKGROUND
BACKGROUND
Large intergenic non-coding RNA regulator of reprogramming (LINC-ROR), as a cancer-related Long non-coding RNA, has vital roles in stem cell survival, pluripotency, differentiation, and self-renewal in human embryonic stem cell. However, cancer-related molecular mech¬anisms, its functional roles, and clinical value of LINC-ROR in gastric cancer (GC) remain unclear. In this study, we aimed to investigate probable interplay between LINC-ROR with SALL4 stemness regulator and their role with the development of the disease.
METHODS
METHODS
The mRNA expression profile of LINC-ROR and SALL4 was assessed in tumoral and adjacent non-cancerous tissues of GC patients, using quantitative real-time PCR.
RESULTS
RESULTS
Significant LINC-ROR underexpression and SALL4 overexpression were observed in 55.81% and 75.58% (p < 0.0001) of samples, respectively. The expression of LINC-ROR and SALL4 were significantly correlated with each other (p = 0.044). There was an association between the underexpression of LINC-ROR and sex, stage of tumor progression, tumor type, and location of tumor (p < 0.05), and Helicobacter pylori infection with SALL4 expression (p = 0.036). There were also significant correlations between concomitant mRNA expression of SALL4 and LINC-ROR in tumors located at distal noncardiac, positive for H. pylori infection, tumors with invasion into the muscle layer of the stomach, and grade II tumor (p < 0.05).
CONCLUSION
CONCLUSIONS
The clinical results of the SALL4-LINC-ROR association propose a probable functional interaction between these markers in tumor maintenance and aggressiveness. Our study can help to understand one of the mechanisms involved in the progression of gastric cancer through the function of these regulators.
Identifiants
pubmed: 33745265
doi: 10.29252/ibj.25.3.157
pmc: PMC8183384
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-68Références
Cell Physiol Biochem. 2017;41(6):2399-2410
pubmed: 28463831
Dev Cell. 2013 Apr 15;25(1):1-2
pubmed: 23597480
Front Med (Lausanne). 2017 May 02;4:47
pubmed: 28512631
J Cell Biochem. 2017 May 18;:
pubmed: 28516515
Gastroenterology. 2016 Jan;150(1):64-78
pubmed: 26385073
Oncotarget. 2016 Dec 13;7(50):82770-82782
pubmed: 27835575
J Gastroenterol Hepatol. 2004 Jul;19(7):756-60
pubmed: 15209621
Cancer Cell Int. 2018 Sep 18;18:142
pubmed: 30250400
Br J Cancer. 2013 Jun 25;108(12):2419-25
pubmed: 23660942
Genes Dev. 2011 Sep 15;25(18):1915-27
pubmed: 21890647
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Oncotarget. 2016 Jan 12;7(2):1608-18
pubmed: 26636540
Sci Rep. 2019 Mar 5;9(1):3562
pubmed: 30837492
Oncol Rep. 2011 Oct;26(4):965-70
pubmed: 21725617
Cell Death Discov. 2017 May 29;3:17004
pubmed: 28580169
Oncogenesis. 2016 Nov 7;5(11):e268
pubmed: 27819668
Med Oncol. 2014 Apr;31(4):922
pubmed: 24659265
Biomed Res Int. 2015;2015:737621
pubmed: 26064948
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1328-1333
pubmed: 29358395
World J Gastroenterol. 2018 Sep 7;24(33):3724-3737
pubmed: 30197478
Gynecol Oncol. 2014 May;133(2):333-9
pubmed: 24589415
Biosci Rep. 2018 Sep 28;38(5):
pubmed: 30076198
Cell Physiol Biochem. 2016;40(1-2):219-229
pubmed: 27855392
Nat Genet. 2010 Dec;42(12):1113-7
pubmed: 21057500
Cytoskeleton (Hoboken). 2013 Jul;70(7):349-59
pubmed: 23629919
Oncotarget. 2017 Dec 6;9(2):1915-1930
pubmed: 29416741
Asian Pac J Cancer Prev. ;18(9):2329-2337
pubmed: 28950674
Ecancermedicalscience. 2017 Jan 17;11:714
pubmed: 28144288
Cell Reprogram. 2016 Oct;18(5):319-326
pubmed: 27602437
J Mol Neurosci. 2015 Jul;56(3):623-30
pubmed: 25651893
Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):78-86
pubmed: 27099666
Iran J Basic Med Sci. 2016 Oct;19(10):1131-1135
pubmed: 27872710
Nat Cell Biol. 2006 Oct;8(10):1114-23
pubmed: 16980957
Med Oncol. 2015 Aug;32(8):217
pubmed: 26175262
Sci Rep. 2018 Mar 16;8(1):4680
pubmed: 29549263
J Cell Mol Med. 2014 Dec;18(12):2425-36
pubmed: 25297942
J Cell Sci. 2014 Apr 1;127(Pt 7):1585-94
pubmed: 24463816
Tumour Biol. 2016 Sep;37(9):11701-11709
pubmed: 27444278
Cancer Res. 2011 Jan 1;71(1):3-7
pubmed: 21199792
Mol Med Rep. 2015 Sep;12(3):3223-3230
pubmed: 25997695
Oncotarget. 2017 Sep 18;8(49):86082-86097
pubmed: 29156779
Dev Cell. 2013 Apr 15;25(1):69-80
pubmed: 23541921
Histol Histopathol. 2002 Jan;17(1):323-9
pubmed: 11813881
PLoS One. 2018 Dec 17;13(12):e0209342
pubmed: 30557328
Tumour Biol. 2017 Apr;39(4):1010428317698366
pubmed: 28443494
Int J Biol Markers. 2019 Mar;34(1):69-79
pubmed: 30852975
J Exp Clin Cancer Res. 2017 Dec 13;36(1):182
pubmed: 29237490
Oncotarget. 2017 Dec 16;9(27):19443-19458
pubmed: 29721215
Cell Death Dis. 2014 Jun 12;5:e1287
pubmed: 24922071
Oncotarget. 2016 Feb 23;7(8):8601-12
pubmed: 26788991
Tumour Biol. 2016 Feb;37(2):1763-9
pubmed: 26314857
Cell Mol Life Sci. 2019 Apr;76(8):1459-1471
pubmed: 30607432
J Cancer Res Clin Oncol. 2015 Feb;141(2):229-35
pubmed: 25156818